The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 75, Issue 2, 2006, Pages 117-126

  Lourida, Evangelia S ^a   Papathanasiou, Athanasios I ^b   Goudevenos, John A ^b   Tselepis, Alexandros D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIGEN; AUTOANTIBODY; COPPER; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DECOMPOSITION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; STABLE ANGINA PECTORIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; ANTIGENS; AUTOANTIBODIES; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPID METABOLISM; LIPOPROTEINS, LDL; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; OXIDATION-REDUCTION;

ANGINA;

EID: 33747830793     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2006.03.012     Document Type: Article

References (30)

1. Bhakdi S.L.K., Han S.-R., Torzewski M., and Husmann M. Beyond cholesterol: the enigma of atherosclerosis revised. Thromb. Haemost. 91 (2004) 639-645
2. Scott J. Pathophysiology and biochemistry of cardiovascular disease. Curr. Opin. Genet. Dev. 14 (2004) 271-279
3. Tselepis A.D., and Chapman M.J. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis (Suppl) 3 4 (2002) 57-68
4. Karasawa K., Harada A., Satoh N., Inoue K., and Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog. Lipid. Res. 42 (2003) 93-114
5. Liapikos Th.A., Antonopoulou S., Karabina S.-A.P., Tsoukatos D.C., Demopoulos C.A., and Tselepis A.D. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim. Biophys. Acta. 1212 (1994) 353-360
6. Berliner J.A., Subbanagounder G., Leitinger N., Watson A.D., and Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends.Cardiov.Med. 11 (2001) 142-147
7. Parthasarathy S., Weiland E., and Steinberg D. A role of endothelial cell lipoxyganase in the oxidative modification of low density lipoprotein. Proc. Natl. Acad. Sci. USA 86 (1989) 1046-1050
8. Fukumoto M., Shoji T., Emoto M., Kawagishi T., Okuno Y., and Nishizawa Y. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler. Thromb. Vasc. Biol. 20 3 (2000) 703-707
9. Hammer A., Kager G., Dohr G., Rabl H., Ghassempur I., and Jurgens G. Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15 5 (1995) 704-713
10. Sakata N., Imanaga Y., Meng J., Tachikawa Y., Takebayashi S., Nagai R., Horiuchi S., Itabe H., and Takano T. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis 141 1 (1998) 61-75
11. Salonen J.T., Yla-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyssonen K., Palinski W., and Witztum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 8798 (1992) 883-887
12. Chiesa R., Melissano G., Castellano R., Astore D., Marone E.M., Grossi A., Maggi E., Finardi G., Casasco A., and Bellomo G. In search of biological markers of high-risk carotid artery atherosclerotic plaque: enhanced LDL oxidation. Ann. Vasc. Surg. 12 1 (1998) 1-9
13. Holvoet P., and Collen D. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis 137 Suppl (1998) S33-S38
14. Monaco C., Crea F., Niccoli G., Summaria F., Cianflone D., Bordone R., Bellomo G., and Maseri A. Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease; pathophysiological implications. Eur. Heart. J. 22 17 (2001) 1572-1577
15. R. Wu, S. Nityanand, L. Berglund, H. Lithell, G. Holm, A.K. Lefvert, Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction, Arterioscler. Thromb. Vasc. Biol. 17(11) (1997) 3159-3163.
16. Edelstein C., Pfaffinger D., Hinman J., Miller E., Lipkind G., Tsimikas S., Bergmark C., Getz G.S., Witztum J.L., and Scanu A.M. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J. Biol. Chem. 278 52 (2003) 52841-52847
17. Wu R., Huang Y.H., Elinder L.S., and Frostegard J. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 18 4 (1998) 626-630
18. Wu R., de Faire U., Lemne C., Witztum J.L., and Frostegard J. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 33 1 (1999) 53-59
19. Dentan C., Tselepis A.D., Chapman M.J., and Ninio E. Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim. Biophys. Acta. 1299 (1996) 353-357
20. Karabina S.-A.P., Liapikos Th.A., Grekas G., Goudevenos J., and Tselepis A.D. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein. Biochim. Biophys. Acta 1213 (1994) 34-38
21. Bligh E.G., and Dyer W. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37 (1959) 911-917
22. Craig W.Y., Raytcheva S.E., Poulin S.E., and Ritchie R.F. Effect of low-density lipoprotein (LDL) antigen source on an enzyme-linked immunosorbent assay for autoantibodies against oxidized LDL. Ann. Clin. Biochem. 36 3 (1999) 333-339
23. Craig W.Y., Rawstron M.W., Rundell C.A., Robinson E., Poulin S.E., Neveux L.M., Nishina P.M., and Keilson L.M. Relationship between lipoprotein- and oxidation-related variables and atheroma lipid composition in subjects undergoing coronary artery bypass graft surgery. Arterioscler. Thromb. Vasc. Biol. 19 6 (1999) 1512-1517
24. Tsimihodimos V., Karabina S.-A.P., Tambaki A.P., Bairaktari E., Miltiadous G., Goudevenos J.A., Cariolou M.A., Chapman M.J., Tselepis A.D., and Elisaf M. Altered distribution of PAF-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J. Lipid. Res. 43 (2002) 256-263
25. Glantzounis G.K., Tselepis A.D., Tambaki A.P., Trikalinos T.A., Manataki A.D., Galaris D.A., Tsimoyiannis E.C., and Kappas A.M. Laparoscopic surgery-induced changes in oxidative stress markers in human plasma. Surg. Endosc. 15 11 (2001) 1315-1319
26. Karabina S.-A.P., Elisaf M.C., Bairaktari E., Tzallas C., Siamopoulos K.C., and Tselepis A.D. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur. J. Clin. Invest. 27 (1997) 595-602
27. Holvoet P., Collen D., and Van de Werf F. Malondialdehyde- modified LDL as a marker of acute coronary syndromes. J.Am.Med.Assoc. 281 18 (1999) 1718-1721
28. Kwon K.H., Kwon H.M., Hong B.K., Kim D.S., Lee J.Y., Ryu S.K., Park B.E., Park H.Y., Kim J.H., Yoon Y.W., Cho S.Y., and Kim H.S. Autoantibody against, malondialdehyde-modified low density lipoprotein in patients with non-diabetic unstable angina: a potential role in immunologic reaction of plaque instability. Yonsei. Med. J. 43 2 (2002) 203-210
29. Tsimikas S., Bergmark C., Beyer R.W., Patel R., Pattison J., Miller E., Juliano J., and Witztum J.L. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J. Am. Coll. Cardiol. 41 3 (2003) 360-370
30. Tsimikas S., Lau H.K., Han K.R., Shortal B., Miller E.R., Segev A., Curtiss L.K., Witztum J.L., and Strauss B.H. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a). Circulation 109 (2004) 3164-3170